Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2025 ∙ Ul Haq, M. Z. Irfan, H. Shah, M. S. U. Sumbal, A. Mughal, S. Ashraf, S. Basaria, A. A. A. Abdullah, Chacho, M. A. Ayalew, B. D.

Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis

  • Newborn
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Regmi, S. Pande, R. Wyatt, T. H. Niederhauser, V.

Impact of COVID-19 on Parental Barriers to Childhood Vaccination: A Systematic Review

  • Americas
  • United States of America
  • Newborn
  • Children
  • Adolescents
  • Parents/caregivers
  • COVID-19
  • Hepatitis B
  • Rotavirus
  • Diphtheria
  • Tetanus
  • Pertussis
  • Haemophilus influenzae type B
  • Pneumococcal disease
  • Poliomyelitis
  • Influenza
  • Measles
  • Mumps
  • Rubella
  • Varicella
  • Hepatitis A
  • Acceptance
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Amare, S. N. Yee, K. C. Leung, M. Naunton, M. Bushell, M.

Impact of pharmacist-led interventions on COVID-19, herpes zoster, influenza, pneumococcal, and respiratory syncytial virus vaccines uptake in people aged 60 years and older: Systematic review and meta-analysis

  • Adults
  • Older adults
  • Herpes zoster
  • Influenza
  • Pneumococcal disease
  • RSV (Respiratory syncytial virus)
  • COVID-19
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Waszkiewicz, M. Wnuk, K. Switalski, J. Augustynowicz, A.

Knowledge, attitudes, and beliefs of pharmacists regarding vaccinations against influenza and pneumococci - a systematic review

  • Healthcare workers
  • Influenza
  • Pneumococcal disease
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Baiocchi, C. Bhardwaj, M.

Parental vaccine refusal, non-vaccinated children, and outbreaks of Vaccine-Preventable Diseases (VPDs) in Europe: a systematic review of aetiology and risk

  • Europe
  • Newborn
  • Children
  • Adolescents
  • Parents/caregivers
  • Diphtheria
  • Haemophilus influenzae type B
  • Hepatitis B
  • Human papillomavirus (HPV)
  • Measles
  • Rubella
  • Mumps
  • Pertussis
  • Pneumococcal disease
  • Poliomyelitis
  • Tetanus
  • Acceptance
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Mariscal-Lopez, E. Agredano-Sanchez, M. Lopez-Gigosos, R. M. Mariscal, A. Farinas-Guerrero, F. Gutierrez-Bedmar, M. Guts-Chornoknyzha, M.

Protective effect of adult vaccination on the development of dementias: A systematic review

  • Adults
  • Older adults
  • Influenza
  • Tetanus
  • Diphtheria
  • Pertussis
  • Herpes zoster
  • Pneumococcal disease
  • Tuberculosis
  • Rabies
  • Hepatitis A
  • Typhoid
  • Hepatitis B
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Cho, J. Y. Lee, H. Wannaadisai, W. Vietri, J. Chaiyakunapruk, N.

Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines

  • Adults
  • Older adults
  • Pneumococcal disease
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Holland, C. Oakes, D. Sarna, M. Chai, K. Ng, L. Moore, H. C.

Systematic review and meta-analysis of the non-specific and broader impact of respiratory vaccines on acute lower respiratory infections in young children

  • Newborn
  • Children
  • Pregnant women
  • Influenza
  • Haemophilus influenzae type B
  • RSV (Respiratory syncytial virus)
  • Measles
  • Pneumococcal disease
  • Diphtheria
  • Tetanus
  • Pertussis
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Lee, H. Cho, J. Y. Vietri, J. Dawson, E. Chaiyakunapruk, N.

The incremental net monetary benefit of higher-valent pneumococcal conjugate vaccines for adults: a systematic review and meta-analysis of economic evaluations

  • Adults
  • Older adults
  • Pneumococcal disease
  • Economic aspects
  • Administration
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Hirsch, C. Zorger, A. M. Baumann, M. Park, Y. S. Bröckelmann, P. J. Mellinghoff, S. Monsef, I. Skoetz, N. Kreuzberger, N.

Vaccines for preventing infections in adults with solid tumours

  • Adults
  • Older adults
  • Pneumococcal disease
  • Haemophilus influenzae type B
  • Meningococcal disease
  • Pertussis
  • Hepatitis B
  • Tetanus
  • Poliomyelitis
  • Diphtheria
  • Influenza
  • Herpes zoster
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
Loading...